Notre Dame Law School

Notre Dame Law School, part of the University of Notre Dame founded in 1842, is located in Notre Dame, Indiana. The school is recognized for its rigorous academic programs and commitment to values that integrate faith and knowledge. It attracts a diverse student body from all 50 states and over 100 countries, fostering a collaborative and enriching learning environment. The Law School benefits from the university's substantial endowment fund, which supports scholarships, faculty positions, and various academic initiatives. The campus is known for its collegiate Gothic architecture and picturesque landscape, contributing to a unique educational atmosphere that emphasizes both tradition and innovation. Notre Dame Law School stands out not only for its academic excellence but also for its dedication to cultivating a sense of community and moral integrity among its students.

John A. Barker

Senior Associate

Patricia F. Brady

Associate

Rick Buhrman

Investment Director

Michael A. Cook

Investment Director, Real Estate

Thomas J. Gotsch

Director of Portfolio Accounting and Operations

William D. James

Investment Director

Mark C. Krcmaric

MD for Finance and Administration

Sushma Lakkaraju

Investment Accountant and Operations Associate

David J. Ludwig

Director of Technology and Performance Analytics

Drew Paluf

Associate Vice President and Controller

2 past transactions

Torigen Pharmaceuticals

Venture Round in 2022
Torigen Pharmaceuticals is a company focused on being at the forefront of immuno-oncology innovation. They strive to bring novel approaches to the market to tackle companion animal cancers, building on years of existing scientific research and pushing the boundaries of innovation.

AgenDx Biosciences

Seed Round in 2018
AgenDx is an early stage molecular diagnostics company developing a revolutionary cost-effective molecular diagnostics platform. Their novel technology allows simple molecular diagnostic lab-quality testing. With a quick sample-to-answer in minutes, their platform is positioned to transform where and how disease is detected and treated. Their platform accommodates a wide range of nucleic-acid based tests for infectious disease, cancer, and other chronic conditions including cardiovascular disease and arthritis. Their initial focus is to prove the AgenDx technology by developing tests for aiding physician’s treatment decisions for pancreatic cancer. Their platform is designed for operation by untrained users in clinical settings near the patient. The sample is collected and inserted into a disposable cartridge. A control system automates and runs the test. Clear results will be displayed and transmitted. Their proprietary system will accommodate any biological sample, including blood, saliva, and tissue.